26 May 2023
Research presented at the European Congress on Obesity has identified a link between semaglutide, a common weight-loss drug, and a notable reduction in cardiovascular risks in patients with obesity after one year of use. The study concludes the importance of weight-loss in these improvements.
Join the Clinical Committee as a Co-Opted Member
18 Sep 2023
Update from Ferring Pharmaceuticals regarding Desmopressin
18 Sep 2023
Link between premenopausal bilateral oophorectomy and chronic illness
15 Sep 2023
COVID-19 vaccination associated with risk of thyroid associated eye disease
15 Sep 2023
Breakthrough AI system may improve treatment of debilitating diseases
15 Sep 2023
